Écrit par GlobalData | 17 Mai 2017

One of the most pressing unmet needs in the human immunodeficiency virus (HIV) market, which is set to reach $22.5 billion by 2025, lies in the current lack of long-acting and safer treatments, according to research and consulting firm GlobalData.

The company’s report states that adherence to antiretroviral therapy (ART) is a significant concern in the treatment of HIV, and current...

Écrit par MERCK | 17 Mai 2017

Merck aims to build hypertension experts platform across the globe through call for 2017 Hypertension Award applications to mark World Hypertension Day

KAMPALA, Uganda, May 17, 2017/ -- Merck (www.MerckGroup.com), a leading science and technology company in healthcare, life science and performance materials, marks today World Hypertension Day with the announcement of the 2016 ‘Merck...

Écrit par VALBIOTIS | 16 Mai 2017

VALBIOTIS LANCE SON INTRODUCTION EN BOURSE SUR LE MARCHE ALTERNEXT PARIS




• Offre au public d'un montant de 10,0 M€ (sur la base du point médian de la fourchette de prix) pouvant être porté à 11,5 M€ en cas d'exercice intégral de la clause d'extension et à 13,2 M€ en cas d'exercice intégral de la clause d'extension et de l'option de surallocation




• Fourchette indicative...

Écrit par MERCK | 16 Mai 2017

Accelerates development timelines with faster, easier selection and scale up of clones
Delivers higher titers of recombinant proteins

Darmstadt, Germany, May 16, 2017 — Merck today announced that its CHOZN® expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic.

The CHOZN® expression system is...